Vertex Pharmaceuticals Incorporated ($VRTX) Stock Forecast: Up 2.2% Today

What is Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals (VRTX): Vertex Pharmaceuticals is a renowned biopharmaceutical company known for its work in cystic fibrosis and other serious diseases. The company is set to participate in upcoming investor conferences to provide further updates on its operations and pipeline.

Why is Vertex Pharmaceuticals Incorporated going up?

VRTX stock is up 2.2% on May 12, 2026 14:36

• VRTX's stock price increased by 1.24% to $435.17, outperforming competitors on a strong trading day.
• Positive market sentiment and overall market growth, evidenced by the rising S&P 500 Index and the Dow Jones Industrial Average, contributed to the bullish movement in VRTX's stock price.
• Investor optimism and confidence in the company's future prospects may have been bolstered by the upcoming investor conferences where Vertex will provide updates.
• The positive momentum in VRTX's stock price contrasts with challenges faced by other biotech companies, highlighting investor interest in companies with promising pipelines like CRISPR Therapeutics.

VRTX Price Chart

VRTX Technical Analysis

VRTX News

Biohaven (BHVN) Valuation Check After Q1 Results And New Shelf Registration

Biohaven (BHVN) is under scrutiny after its Q1 results and a new shelf registration. Despite a reduced net loss, its share price has fallen significantly, leading to questions about its valuation. The company's Price-to-Book ratio of 10.6x is below peers but well above the biotech sector, indicating that its current market value relies heavily on expectations for its extensive pipeline rather than current profitability.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/biohaven-bhvn-valuation-check-after-q1-results-and-new-shelf

1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?

A top Wall Street analyst believes CRISPR Therapeutics (CRSP) could more than double, with Piper Sandler's Edward Tenthoff setting a $110 price target. This bullish sentiment is fueled by potential catalysts like upcoming clinical trial data readouts for candidates such as the anticoagulant CTX611 and potential expansion of its approved product, Casgevy, to younger patients. While the stock carries risk due to its volatility and reliance on clinical success, its innovative gene-editing platform and robust pipeline, backed by $2.4 billion in cash, suggest promising long-term growth for investors with a high risk tolerance.

https://www.fool.com/investing/2026/05/11/1-top-wall-street-analyst-thinks-crispr-therapeuti/

Septerna, Inc. 1Q 2026: Revenue $26.5M, EPS $(0.19) — 10-Q Summary

Septerna, Inc. reported its first-quarter 2026 financial results, with revenue reaching $26.5 million, significantly up from $0.2 million in Q1 2025, primarily due to research services under its Novo collaboration. The company narrowed its net loss to $(8.6) million and achieved a diluted loss per share of $(0.19). Septerna also highlighted key business developments, including the dosing of first participants in a Phase 1 clinical trial and strong liquidity with $522.1 million in cash, expected to fund operations into 2029.

https://www.tradingview.com/news/tradingview:9371fb5850b9e:0-septerna-inc-1q-2026-revenue-26-5m-eps-0-19-10-q-summary/

Vertex to Participate in Upcoming May Investor Conferences

Vertex Pharmaceuticals Incorporated announced its management will participate in two investor conferences in May 2026. Charlie Wagner, COO and CFO, will speak at the RBC Capital Markets Global Healthcare Conference on May 19, 2026, and Dr. Reshma Kewalramani, CEO and President, will participate in Bernstein’s 42nd Annual Strategic Decisions Conference on May 29, 2026. The company, known for its work in cystic fibrosis and other serious diseases, will provide further updates at these events.

https://www.businesswire.com/news/home/20260511401202/en/Vertex-to-Participate-in-Upcoming-May-Investor-Conferences

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Vertex Pharmaceuticals Inc. (VRTX) saw its stock increase by 1.24% to $435.17 on Monday. This gain occurred during a generally positive trading session where both the S&P 500 Index and the Dow Jones Industrial Average also rose by 0.19%. This marks the second consecutive day of gains for Vertex Pharmaceuticals' stock, outperforming its competitors.

https://www.marketwatch.com/data-news/vertex-pharmaceuticals-inc-stock-outperforms-competitors-on-strong-trading-day-84406b3b-a1866617a6fb?mod=mw_quote_news

Trending Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.1% Today

Solana ($SOL) Crypto Forecast: Down 5.6% Today

Advance Auto Parts Inc W/I ($AAP) Stock Forecast: Down 5.1% Today

NRG Energy Inc. ($NRG) Stock Forecast: Down 5.0% Today

Ubiquiti ($UI) Stock Forecast: Down 5.2% Today

Franco-Nevada Corp. ($FNV) Stock Forecast: Down 5.2% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Up 11.1% Today

Ford Motor Company ($F) Stock Forecast: Down 7.1% Today

ServiceNow Inc. ($NOW) Stock Forecast: Up 5.0% Today

Kornit Digital Ltd. ($KRNT) Stock Forecast: Down 5.4% Today

Vertex Pharmaceuticals Incorporated Price History

03.11.2025 - VRTX Stock was up 5.9%

• An upgrade from a major financial institution to an Overweight rating for Vertex's stock and an increase in the price target, driven by the potential of the kidney pipeline candidates Pove and Inaxaplin, have boosted investor confidence in the company's expansion into new treatment areas.
• The addition of Duncan McKechnie as the Executive Vice President and Chief Commercial Officer brings extensive experience in commercial operations to Vertex, potentially enhancing the company's global commercial strategies and market presence.
• Vertex's solid financial standing, positive results from clinical trials of its kidney therapy, and expectations of growth in revenue and earnings from 2025 to 2035 have all contributed to the positive market outlook for the stock.
• Despite concerns about the company's reliance on cystic fibrosis treatments and pricing challenges, investors are monitoring Vertex's valuation, growth projections, and research and development efforts to evaluate its potential for growth in the competitive pharmaceutical industry.

03.11.2025 - VRTX Stock was up 6.3%

• VRTX stock surged by 6.2% following an upgrade to "Overweight" with a new price target of $516, driven by optimism surrounding the potential of Vertex's kidney drug pipeline, specifically Pove and Inaxaplin.
• The upgrade reflects confidence in Vertex's pipeline diversity and the shift towards valuing drugmakers based on long-term chronic disease solutions, beyond the traditional cystic fibrosis franchise.
• The appointment of Duncan McKechnie as the Executive Vice President and Chief Commercial Officer also signals strong leadership within the company, further boosting investor confidence in Vertex's strategic direction and commercial activities.
• Despite facing challenges in its cystic fibrosis business, Vertex's promising clinical trial data for its investigational kidney therapy, povetacicept, is expected to drive accelerated revenue and earnings growth between 2025 and 2035, positioning the company for long-term success in the pharmaceutical industry.

13.01.2026 - VRTX Stock was up 8.0%

• Vertex Pharmaceuticals (VRTX) saw a notable upward trend in the market due to positive analyst evaluations and coverage, indicating substantial growth prospects in its renal pipeline and non-cystic fibrosis products.
• The company's impressive financial results in Q4 2025, showcasing significant revenue growth and successful product introductions, contributed to the upbeat market movement.
• Analysts are closely observing Vertex's kidney franchise and advancements in its non-opioid painkiller Journavx, expecting promising outcomes and sustained momentum in the upcoming period.
• The market's favorable reaction to Vertex's strategic foray into gene therapy and pain management, along with its strong performance in the core cystic fibrosis franchise, likely underpinned the positive trajectory of VRTX stock.

13.01.2026 - VRTX Stock was up 5.4%

• The notable surge in Vertex Pharmaceuticals' stock price can be attributed to its impressive Q4 2025 financial results, indicating a 10% revenue growth year-over-year and a favorable outlook for 2026.
• Investor confidence in the company has been reinforced by its emphasis on the cystic fibrosis segment, successful product launches including KASJEVY and Gernavix, and advancements in other areas such as the renal pipeline with a focus on Povatacept for IgA nephropathy.
• Analysts' generally positive outlook on Vertex Pharmaceuticals, as reflected in a high average 12-month price target and favorable expert opinions, has further bolstered the bullish market sentiment.
• The purchase of Vertex Pharmaceuticals shares by ING Groep NV and other institutional investors indicates a strong belief in the company's future growth potential, underlining the positive sentiment prevailing in the market.

12.04.2026 - VRTX Stock was up 2.2%

• VRTX's stock price increased by 1.24% to $435.17, outperforming competitors on a strong trading day.
• Positive market sentiment and overall market growth, evidenced by the rising S&P 500 Index and the Dow Jones Industrial Average, contributed to the bullish movement in VRTX's stock price.
• Investor optimism and confidence in the company's future prospects may have been bolstered by the upcoming investor conferences where Vertex will provide updates.
• The positive momentum in VRTX's stock price contrasts with challenges faced by other biotech companies, highlighting investor interest in companies with promising pipelines like CRISPR Therapeutics.

06.00.2026 - VRTX Stock was up 5.2%

• Vertex Pharmaceuticals was upgraded by Wolfe Research from "peer perform" to "outperform," with a price target of $548, reflecting optimism about the company's future.
• The company exceeded quarterly earnings expectations, showing strong growth in EPS and revenue, indicating a solid financial performance and potential for further advancement.
• Institutional investors demonstrate continued enthusiasm for Vertex Pharmaceuticals despite insider selling, holding a considerable portion of the company's stock, potentially boosting market confidence.
• The bullish trend in Vertex Pharmaceuticals can be linked to Wolfe Research's upgrade, the company's impressive financial results, and the sustained interest from institutional investors, indicating a positive sentiment towards its growth prospects in the biopharmaceutical industry.

06.00.2026 - VRTX Stock was up 5.0%

• The company was upgraded from "peer perform" to "outperform" by Wolfe Research with a price target of $548, reflecting a positive outlook on its growth prospects.
• Vertex exceeded quarterly earnings estimates with $4.80 EPS and $3.08 billion in revenue, showing 11% year-over-year growth, which contributed to the bullish sentiment.
• Despite insider selling activity, institutional investors owning a significant portion of the company's stock indicate strong confidence in its future performance.
• The upgrade and positive earnings results likely fueled investor optimism and buying interest in Vertex Pharmaceuticals, driving the stock price higher.

10.02.2026 - VRTX Stock was up 10.5%

• Vertex Pharmaceuticals stock surged 5% after successful Phase 3 trial results for its kidney disease drug, povetacicept, showing promising efficacy and safety profile.
• The company's $4.9 billion acquisition of a biotech company focused on kidney disease is nearing an important milestone, suggesting potential positive outcomes for its investment.
• Increased stake by Capital Research Global Investors and positive reactions from analysts indicate growing confidence in Vertex's pipeline and future commercial prospects.
• Market Linked Securities offering by Goldman Sachs Group Inc. linked to Adobe Inc. and CoreWeave, Inc. stocks may have also influenced positive market sentiment towards Vertex Pharmaceuticals, contributing to its bullish movement.

10.02.2026 - VRTX Stock was up 9.4%

• VRTX stock surged by 5% following successful Phase 3 trial results for its kidney disease drug, povetacicept, which showed promising efficacy in reducing proteinuria and maintaining a clean safety profile.
• The positive trial results have sparked investor optimism, leading to an increase in Vertex's stock price and attracting the attention of major institutional investors like Capital Research Global Investors, who have been increasing their stake in the company.
• Analysts have reacted positively to the news, raising price targets for Vertex as the successful drug trial signifies a potential new revenue stream beyond the company's established cystic fibrosis business.
• The bullish movement in VRTX stock also outperformed the broader market, with S&P 500 futures remaining steady in premarket trading, further underscoring the positive sentiment surrounding Vertex Pharmaceuticals.

10.02.2026 - VRTX Stock was up 10.7%

• Vertex Pharmaceuticals experienced a strong bullish movement today, with its stock jumping significantly.
• The positive Phase 3 clinical trial data for its kidney disease drug was a key driver of the stock's rise.
• Reduction in stake by a financial group might have initially raised concerns, but the successful drug trial results reassured investors and led to a rally in the stock.
• Positive sentiment towards the drug's performance from financial analysts further fueled the market's reaction, indicating confidence in Vertex's pipeline and future prospects.

21.00.2026 - VRTX Stock was up 5.0%

• Vertex Pharmaceuticals is a leading biotech company known for its strong cystic fibrosis franchise and innovative therapies. The stock had a bullish movement today amidst positive market sentiment.
• A prominent financial firm reduced its stake in VRTX, but insiders have been selling shares, indicating confidence in the company's performance.
• Analysts maintain a "Moderate Buy" rating with an average target price of $503.80, reflecting optimism in the stock's potential.
• The upcoming announcement of fourth-quarter and full-year 2025 financial results on February 12th creates anticipation and interest among investors.
• Despite recent mixed performance, the stock's undervaluation potential of up to 39% according to a discounted cash flow model could be driving investor interest and contributing to the bullish movement.

05.04.2026 - VRTX Stock was down 1.5%

• Despite a strong performance in Q1 2026 earnings and surpassing EPS expectations, Vertex Pharmaceuticals fell slightly short of revenue predictions, leading to a negative market reaction.
• The sales of newer products, such as CASGEVY and JOURNAVX, did not meet analyst forecasts, which affected investor response and contributed to the stock price decline.
• The market reaction may be due to the discrepancy between the company's strong financial results and the missed revenue projections, suggesting a sense of caution among investors.
• Investors are keeping a close watch on the progress of Vertex's experimental medications like povetacicept, as it could influence future revenue and market sentiment.